Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography.

Lindner S, Michler C, Leidner S, Rensch C, Wängler C, Schirrmacher R, Bartenstein P, Wängler B.

Bioconjug Chem. 2014 Apr 16;25(4):738-49. doi: 10.1021/bc400588e. Epub 2014 Apr 4.

PMID:
24666287
2.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.

PMID:
23969085
3.

One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET).

Wängler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, Jurkschat K, Fottner C, Bartenstein P, Schirrmacher R, Reubi JC, Wester HJ, Wängler B.

Bioconjug Chem. 2010 Dec 15;21(12):2289-96. doi: 10.1021/bc100316c. Epub 2010 Nov 17.

PMID:
21082773
4.

Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics.

Litau S, Niedermoser S, Vogler N, Roscher M, Schirrmacher R, Fricker G, Wängler B, Wängler C.

Bioconjug Chem. 2015 Dec 16;26(12):2350-9. doi: 10.1021/acs.bioconjchem.5b00510. Epub 2015 Oct 14.

PMID:
26420336
5.

In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirrmacher R, Wängler B.

J Nucl Med. 2015 Jul;56(7):1100-5. doi: 10.2967/jnumed.114.149583. Epub 2015 May 14.

6.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

7.

(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Liu Z, Yan Y, Liu S, Wang F, Chen X.

Bioconjug Chem. 2009 May 20;20(5):1016-25. doi: 10.1021/bc9000245.

8.

(18)F-glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation.

Maschauer S, Haubner R, Kuwert T, Prante O.

Mol Pharm. 2014 Feb 3;11(2):505-15. doi: 10.1021/mp4004817. Epub 2013 Dec 16.

PMID:
24325589
9.

64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.

Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.

Nucl Med Biol. 2012 Apr;39(3):377-87. doi: 10.1016/j.nucmedbio.2011.10.004. Epub 2012 Jan 5.

10.

Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.

Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1257-66. doi: 10.1007/s00259-011-1775-3. Epub 2011 Mar 23.

11.

Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M.

J Nucl Med. 2011 Aug;52(8):1276-84. doi: 10.2967/jnumed.111.087700. Epub 2011 Jul 15. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

12.

Rerouting the metabolic pathway of (18)F-labeled peptides: the influence of prosthetic groups.

Richter S, Wuest M, Bergman CN, Way JD, Krieger S, Rogers BE, Wuest F.

Bioconjug Chem. 2015 Feb 18;26(2):201-12. doi: 10.1021/bc500599m. Epub 2015 Jan 26.

PMID:
25572982
13.

In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.

Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V, Orlova A.

PLoS One. 2013 Dec 3;8(12):e81932. doi: 10.1371/journal.pone.0081932. eCollection 2013.

14.

Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.

Richter S, Wuest M, Bergman CN, Krieger S, Rogers BE, Wuest F.

Mol Pharm. 2016 Apr 4;13(4):1347-57. doi: 10.1021/acs.molpharmaceut.5b00970. Epub 2016 Mar 23.

PMID:
26973098
15.

(18)F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging.

Pourghiasian M, Liu Z, Pan J, Zhang Z, Colpo N, Lin KS, Perrin DM, Bénard F.

Bioorg Med Chem. 2015 Apr 1;23(7):1500-6. doi: 10.1016/j.bmc.2015.02.009. Epub 2015 Feb 20.

16.

Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.

Dijkgraaf I, Terry SY, McBride WJ, Goldenberg DM, Laverman P, Franssen GM, Oyen WJ, Boerman OC.

Contrast Media Mol Imaging. 2013 May-Jun;8(3):238-45. doi: 10.1002/cmmi.1523.

17.

Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.

Liu Z, Yan Y, Chin FT, Wang F, Chen X.

J Med Chem. 2009 Jan 22;52(2):425-32. doi: 10.1021/jm801285t.

PMID:
19113865
18.

Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.

Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A.

Bioconjug Chem. 2008 Sep;19(9):1871-9. doi: 10.1021/bc800157h. Epub 2008 Aug 28.

PMID:
18754574
19.

N-Succinimidyl 4-[(18)F]-fluoromethylbenzoate-labeled dimeric RGD peptide for imaging tumor integrin expression.

Li W, Lang L, Niu G, Guo N, Ma Y, Kiesewetter DO, Shen B, Chen X.

Amino Acids. 2012 Sep;43(3):1349-57. doi: 10.1007/s00726-011-1208-4. Epub 2011 Dec 31.

20.

(18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors.

Ma Y, Liang S, Guo J, Guo R, Wang H.

J Labelled Comp Radiopharm. 2014 Sep;57(11):627-31. doi: 10.1002/jlcr.3222. Epub 2014 Oct 8.

PMID:
25294311

Supplemental Content

Support Center